Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Coherus Oncology (CHRS) Equity Ratio (2016 - 2025)

Historic Equity Ratio for Coherus Oncology (CHRS) over the last 13 years, with Q3 2025 value amounting to 0.17.

  • Coherus Oncology's Equity Ratio rose 19754.87% to 0.17 in Q3 2025 from the same period last year, while for Sep 2025 it was 0.17, marking a year-over-year increase of 19754.87%. This contributed to the annual value of 0.29 for FY2024, which is 421.41% up from last year.
  • Coherus Oncology's Equity Ratio amounted to 0.17 in Q3 2025, which was up 19754.87% from 0.27 recorded in Q2 2025.
  • Coherus Oncology's Equity Ratio's 5-year high stood at 0.27 during Q2 2025, with a 5-year trough of 0.49 in Q1 2025.
  • For the 5-year period, Coherus Oncology's Equity Ratio averaged around 0.1, with its median value being 0.12 (2024).
  • As far as peak fluctuations go, Coherus Oncology's Equity Ratio plummeted by 240641.08% in 2023, and later surged by 31877.85% in 2025.
  • Quarter analysis of 5 years shows Coherus Oncology's Equity Ratio stood at 0.14 in 2021, then tumbled by 298.66% to 0.29 in 2022, then dropped by 7.5% to 0.31 in 2023, then rose by 4.21% to 0.29 in 2024, then surged by 157.75% to 0.17 in 2025.
  • Its last three reported values are 0.17 in Q3 2025, 0.27 for Q2 2025, and 0.49 during Q1 2025.